Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study
Dermatitis® · 2024
DOI: 10.1089/derm.2023.0132 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Dermatitis®, 2024. Verfasst von Dawei Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China.
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
- Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
ORCID-Profile: Dawei Huang
Zitieren
APA
Huang, D., Lu, J., & Tan, F. (2024). Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study. Dermatitis®. https://doi.org/10.1089/derm.2023.0132
Vancouver
Huang D, Lu J, Tan F. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study. Dermatitis®. 2024. doi:10.1089/derm.2023.0132
BibTeX
@article{Huang2024,
author = {Huang, Dawei and Lu, Jiajing and Tan, Fei},
title = {Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study},
journal = {Dermatitis®},
year = {2024},
doi = {10.1089/derm.2023.0132}
}
EUVIMED